DK1383507T3 - Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser - Google Patents

Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser

Info

Publication number
DK1383507T3
DK1383507T3 DK02764017T DK02764017T DK1383507T3 DK 1383507 T3 DK1383507 T3 DK 1383507T3 DK 02764017 T DK02764017 T DK 02764017T DK 02764017 T DK02764017 T DK 02764017T DK 1383507 T3 DK1383507 T3 DK 1383507T3
Authority
DK
Denmark
Prior art keywords
intoxications
galanthamine
treatment
nervous system
central nervous
Prior art date
Application number
DK02764017T
Other languages
Danish (da)
English (en)
Inventor
Klaus Opitz
Joachim Moormann
Thomas Hille
Frank Becher
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1383507(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Application granted granted Critical
Publication of DK1383507T3 publication Critical patent/DK1383507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02764017T 2001-04-24 2002-04-18 Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser DK1383507T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119862A DE10119862A1 (de) 2001-04-24 2001-04-24 Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
PCT/EP2002/004277 WO2002085370A1 (de) 2001-04-24 2002-04-18 Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (1)

Publication Number Publication Date
DK1383507T3 true DK1383507T3 (da) 2008-03-17

Family

ID=7682409

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02764017T DK1383507T3 (da) 2001-04-24 2002-04-18 Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser

Country Status (27)

Country Link
US (1) US8207159B2 (pl)
EP (1) EP1383507B1 (pl)
JP (1) JP2004531533A (pl)
KR (1) KR20040005934A (pl)
CN (1) CN100400043C (pl)
AR (1) AR033468A1 (pl)
AT (1) ATE378052T1 (pl)
AU (1) AU2002308148B2 (pl)
BR (1) BR0209126A (pl)
CA (1) CA2444818C (pl)
CZ (1) CZ20032789A3 (pl)
DE (2) DE10119862A1 (pl)
DK (1) DK1383507T3 (pl)
EA (1) EA200301135A1 (pl)
ES (1) ES2296990T3 (pl)
HK (1) HK1062401A1 (pl)
HU (1) HUP0401123A3 (pl)
IL (2) IL158382A0 (pl)
MX (1) MXPA03009765A (pl)
NO (1) NO20034740L (pl)
NZ (1) NZ529004A (pl)
PL (1) PL207525B1 (pl)
PT (1) PT1383507E (pl)
SK (1) SK287235B6 (pl)
TW (1) TWI329512B (pl)
WO (1) WO2002085370A1 (pl)
ZA (1) ZA200308004B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr) 2008-05-06 2010-09-24 Biocodex Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
US20180200259A1 (en) * 2015-05-18 2018-07-19 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOID ß
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3843239C1 (pl) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5015645A (en) * 1989-10-19 1991-05-14 Ciba-Geigy Corporation Tetracyclic pyrrole lactam derivatives
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
US5965571A (en) * 1996-08-22 1999-10-12 New York University Cholinesterase inhibitors for treatment of Parkinson's disease
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
CN1240384C (zh) * 1999-11-04 2006-02-08 美国爱科赛尔制药有限公司 石杉碱经皮给药制剂
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

Also Published As

Publication number Publication date
DE10119862A1 (de) 2002-11-07
SK287235B6 (sk) 2010-04-07
PL207525B1 (pl) 2010-12-31
KR20040005934A (ko) 2004-01-16
BR0209126A (pt) 2004-07-27
ES2296990T3 (es) 2008-05-01
SK13152003A3 (sk) 2004-04-06
CZ20032789A3 (en) 2004-05-12
EP1383507A1 (de) 2004-01-28
EA200301135A1 (ru) 2004-04-29
MXPA03009765A (es) 2005-04-19
HK1062401A1 (en) 2004-11-05
AR033468A1 (es) 2003-12-17
IL158382A (en) 2009-09-01
ATE378052T1 (de) 2007-11-15
US20040116406A1 (en) 2004-06-17
PT1383507E (pt) 2008-02-20
CN1505516A (zh) 2004-06-16
CA2444818A1 (en) 2002-10-31
CA2444818C (en) 2009-06-16
TWI329512B (en) 2010-09-01
IL158382A0 (en) 2004-05-12
NO20034740D0 (no) 2003-10-23
WO2002085370A1 (de) 2002-10-31
US8207159B2 (en) 2012-06-26
AU2002308148B2 (en) 2006-11-02
EP1383507B1 (de) 2007-11-14
HUP0401123A2 (hu) 2004-09-28
JP2004531533A (ja) 2004-10-14
DE50211207D1 (de) 2007-12-27
CN100400043C (zh) 2008-07-09
NO20034740L (no) 2003-10-23
NZ529004A (en) 2007-01-26
HUP0401123A3 (en) 2008-01-28
ZA200308004B (en) 2004-02-11
PL366840A1 (pl) 2005-02-07

Similar Documents

Publication Publication Date Title
DK1572215T3 (da) Benzo[D]azepin-derivater til behandling af neurologiske lidelser
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1598333T3 (da) Fremgangsmåde til fremstilling af (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutan og syreadditionssalte heraf samt anvendelse til syntese af ivabradin og syreadditionssalte heraf med farmaceutisk acceptable syrer
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
NO20034864L (no) Preparat for behandling av legemiddelindusert forstoppelse med 15-keto-prostaglandiner
DK1667967T3 (da) Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
DK1200081T3 (da) Anvendelse af escitalopram til behandling af generaliseret angstlidelse
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
DK1458386T3 (da) Aroylpyrrolheteroaryl- og methanolforbindelser til behandling af en lidelse i centralnervesystemet
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1383507T3 (da) Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1656365T3 (da) Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin
NO20032156D0 (no) Behandling av angstforstyrrelser
DK1351697T3 (da) Lægemiddel til fremme af regenerationen af væv